Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Aphton's Chief Medical Officer Delivers Keynote Address at the 15th International Congress on Anti-Cancer Treatment.


Business Editors/Health/Medical Writers

International Congress on Anti-Cancer Treatment

BIOWIRE2K

MIAMI--(BUSINESS WIRE)--Feb. 12, 2004

Aphton Corporation (Nasdaq:APHT APHT Advance Physical Test ) today announced that its Senior Vice-President and Chief Medical Officer, Dov Michaeli, MD, Ph.D., delivered the keynote address keynote address
n.
An opening address, as at a political convention, that outlines the issues to be considered. Also called keynote speech.

Noun 1.
 in a symposium on "Shifting Paradigms In GI Oncology." The presentation took place yesterday at the 15th "International Congress on Anti-Cancer Treatment" in Paris, France, attended by leading clinicians and drug companies from Europe, the United States and Japan. The title of his address was "Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller  of Upper GI Cancers: a Clinical Perspective." In his talk Dr. Michaeli surveyed the recent developments in understanding the molecular basis of stomach and esophageal cancers, and proposed a new basis for developing combination therapies for these cancers. In this context, Dr. Michaeli's address focused on gastrin, the target of Aphton's product candidate G17DT, and the central role that gastrin plays in the onset, growth, proliferation and metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases  
1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to
 of upper gastrointestinal adenocarcinomas.

Aphton Corporation is a biopharmaceutical company developing products using its innovative targeted immunotherapy technology for neutralizing hormones that participate in gastrointestinal system gastrointestinal system: see digestive system.  and reproductive system reproductive system, in animals, the anatomical organs concerned with production of offspring. In humans and other mammals the female reproductive system produces the female reproductive cells (the eggs, or ova) and contains an organ in which development of the fetus  cancer and non-cancer diseases. Aphton has strategic alliances with Aventis Pasteur for treating gastrointestinal system and other cancers with G17DT in North America and Europe; GlaxoSmithKline for reproductive system cancer and non-cancer diseases worldwide.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Feb 12, 2004
Words:218
Previous Article:Jupitermedia's Search Engine Strategies Conference & Expo to Be Held March 1-4, 2004 in New York City is the Largest to Date.
Next Article:E.piphany Achieves the Only 'Positive' Rating in Research Firm's E-Marketing Vendor MarketScope.
Topics:



Related Articles
Increased Survival Results of Advanced Colorectal Cancer Patients in Phase I/II Clinical Trial Announced by Aphton.
AUSTRALIA GRANTS ORPHAN-DRUG DESIGNATION FOR APHTON'S G17DT.
Fast Track Designation Approved by FDA for Aphton's G17DT Anti-Gastrin Immunogen for Gastric Cancer Therapy.
Patrick T. Mooney, MD, Joins Aphton's Executive Management Team and is Appointed Chief Medical Officer.
GPC BIOTECH GETS U.S. PATENT FOR ANTI-CANCER CELL INHIBITOR.
Aphton Submits Regulatory Application in Canada for Insegia as Monotherapy for Pancreatic Cancer.
Aphton and XOMA Form Therapeutic Antibody Collaboration for Treating Gastrointestinal Cancers.
Aphton Corporation to Acquire Igeneon Extending its Leadership Position in Cancer Immunotherapy; Acquisition Represents Pivotal Step to Establishing...
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE PACT.
Aphton Corporation Reports Fourth Quarter and Year End 2004 Financial Results and Developments.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles